Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES

This announcement is made by CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, collectively the "**Group**") pursuant to Rules 13.51B(2) and 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The Company was informed by Mr. PAN Weidong ("**Mr. PAN**"), an Executive Director of the Company, that he has recently received the "Decision on Administrative Penalty" (the "**Decision**") issued by the China Securities Regulatory Commission (the "**CSRC**") in relation to the following matters:

1. According to the announcement published on 8 December 2023 by CSPC Innovation Pharmaceutical Co., Ltd. ("**CSPC Innovation**"), an indirect non-wholly owned subsidiary of the Company whose shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765), CSPC NBP Pharmaceutical Co., Ltd. ("**NBP**"), a wholly-owned subsidiary of the Company and the largest shareholder of CSPC Innovation, intended to increase its shareholding in CSPC Innovation by an amount not more than RMB100 million within six months commencing from 8 December 2023.

2. On 10 January 2024, CSPC Innovation published an announcement regarding the suspension of trading in relation to the proposed acquisition of CSPC Baike (Shandong) Biopharmaceutical Co., Ltd., another wholly-owned subsidiary of the Company, and the proposed fundraising in support thereof (the "**Restructuring Transaction**"). The work relating to the Restructuring Transaction at that time was led by Mr. PAN, who was then the chairman of CSPC Innovation.

3. Upon investigation, the CSRC considered that, prior to its public disclosure, the Restructuring Transaction constituted an inside information, and that Mr. PAN became aware of such inside information by no later than 5 December 2023. Before the Restructuring Transaction was made public, Mr. PAN used NBP's securities account to acquire an aggregate of 2,742,580 shares of CSPC Innovation (the "**Additional Shares**") during the period from 8 December 2023 to 20 December 2023, with an aggregate acquisition amount of RMB99,988,758.56.

4. The CSRC considered that Mr. PAN violated the relevant provisions of the "Securities Law of the People's Republic of China" (the "**Securities Law**"), and that the above conduct constituted an insider trading under the Securities Law. Accordingly, the CSRC ordered Mr. PAN to deal with the illegally held securities in accordance with the law, and imposed a fine of RMB5 million.

CSPC Innovation published the announcements in relation to the Additional Shares on 8 December 2023 and 21 December 2023 respectively. As disclosed in CSPC Innovation's announcement dated 28 April 2025, the Restructuring Transaction has been terminated and ultimately did not proceed to completion.

Mr. PAN resigned as the chairman of CSPC Innovation on 23 September 2024. According to the Decision, Mr. PAN has the right to apply to the CSRC for administrative review or to initiate administrative litigation in accordance with the law. As at the date of this announcement, the Company holds 1,037,058,294 shares and 11,587,212 shares of CSPC Innovation, through NBP and CSPC Ouyi Pharmaceutical Co., Ltd., another wholly-owned subsidiary of the Company respectively, representing approximately 74.66% of the total issued share capital of CSPC Innovation in aggregate (including the Additional Shares, which represent approximately 0.23% of the total issued share capital of CSPC Innovation).

As at the date of this announcement, the Group's business operations are normal. To the best of the knowledge and information of the Company, the above penalty matter is not expected to have an adverse impact on the Group's business and/or operations.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 3 November 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.